RxDoctor Payments Data

Leigh Bornstein Lurie, MD

Gastroenterology · Rockville, MDNPI 1427225887

Payments from drug & device makers

$2,921in general payments, 2019–2025

Across 128 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$611
  • Takeda Pharmaceuticals U.S.A., Inc.$333
  • Bristol Myers Squibb$301
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$257
  • Johnson & Johnson$248
  • Regeneron Healthcare Solutions, Inc.$149
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,90399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,921 in reported general payments places this provider in the 45th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$365,528
Medicare patients
430
Services billed
16,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$478,350
CreonLipase/Protease/Amylase21$48,394
LinzessLinaclotide20$25,636
XifaxanRifaximin11$24,596
Mesalamine17$23,168
MotegrityPrucalopride Succinate16$12,443
ClenpiqSod Picosulf/Mag Ox/Citric Ac61$10,467
Dexlansoprazole DrDexlansoprazole31$9,909
Pantoprazole Sodium238$3,355
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C12$1,693
Famotidine86$1,449
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates20$1,155
Rabeprazole Sodium21$798
Omeprazole40$739
Sucralfate14$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$248$478,35017 claims
AbbVieCreon, Linzess$611$74,02941 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$257$26,28923 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$333$12,44316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →